This study demonstrated that NXT could effectively treat early-stage AS induced by HCD in mice. NXT regulated the gut microbiota and metabolites, maintained intestinal homeostasis, and improved the systemic inflammatory response. These findings may provide robust experimental support for the clinical use of NXT for AS treatment.

Sim attenuates silica-induced pulmonary inflammation and fibrosis by downregulating EMT and oxidative stress through the AMPK-NOX pathway.

ATV also improved epithelial barrier function by upregulating the mRNA transcript levels of mucin 2 (MUC2), and ZO-1 and occludin tight junction proteins. The results suggest that the ATV anti-inflammatory and protective effects on 5-FU-induced mice mucositis involve the inhibition of the TLR4/MYD88/NPRL3/NF-κB, iNos, and caspase 3.

P4, N=54, Not yet recruiting, Assiut University

P1, N=50, Recruiting, Children's Mercy Hospital Kansas City | Trial completion date: Apr 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jan 2025

Further, In vivo study was also carried out using Ehrlich breast cancer model in mice. Caspase-3 apoptotic marker revealed superior antineoplastic and apoptosis-inducing activity in the groups treated with ATR Ca-SLNs either decorated/ undecorated with Lf in dosage 10 mg/kg/day p < 0.001 with superior activity for lactoferrin-decorated formulation.

In this study, we investigated the effect of Ze 117 on that of dexamethasone and simvastatin. This effect is reflected in an altered signal transduction of the 5-HT1a receptor under Ze 117 administration. The current in vitro results support the hypothesis that Ze 117 addresses relevant parts of the cellular lipid metabolism, possibly explaining some of the antidepressant actions of Ze 117.

P4, N=105, Recruiting, Seoul National University Bundang Hospital | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Dec 2025

P2, N=30, Enrolling by invitation, University of Southern California | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

P1/2, N=130, Recruiting, Beijing Inno Medicine Co., Ltd. | Phase classification: P1 --> P1/2

P=N/A, N=10, Not yet recruiting, Cairo University

Its anticancer activity was primarily due to the induction of G1/S phase arrest as discovered through cell cycle analysis of HepG2 cancer cells. Ultimately, treating HepG2 cancer cells with Pitavastatin affected significant activation of caspase-3 accompanied by down-regulation of cellular apoptotic biomarkers such as IDO, TDO, STAT3, P21, P27, IL-6, and AhR.

P2, N=36, Recruiting, Medical University of South Carolina | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P=N/A, N=8606, Recruiting, Boryung Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting

P4, N=280, Active, not recruiting, Samsung Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Jan 2027

Overexpression of MRPS27 attenuated the stemness-inhibitory effect of lovastatin in TNBC cells. Our findings reveal that dysregulated ribosome biogenesis is a targetable vulnerability and targeting MRPS27 could be a novel therapeutic strategy for TNBC patients.

P=N/A, N=20, Completed, University at Buffalo | Unknown status --> Completed | Phase classification: P3 --> PN/A

P1/2, N=22, Not yet recruiting, Johns Hopkins University

P=N/A, N=105, Not yet recruiting, Assiut University

P2, N=59, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> May 2023

In addition, Rap1 was likely not geranylgeranylated. Our results demonstrate that simvastatin affects actin dynamics by modifying small GTPases, thereby activating the spindle assembly checkpoint and causing abnormal cell division.

P4, N=70, Completed, Seoul National University Bundang Hospital

P=N/A, N=20, Recruiting, Kafrelsheikh University | Trial primary completion date: Aug 2022 --> Aug 2024 | Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Aug 2024

P3, N=600, Recruiting, Kafrelsheikh University

P3, N=600, Recruiting, Kafrelsheikh University

P1, N=46, Completed, JW Pharmaceutical

Male C57BL/6 mice were categorized into four groups: normal diet, high-fat diet (HFD), HFD + atorvastatin 10 mg/kg, and HFD + SSA 10 mg/kg...In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.

P=N/A, N=120, Recruiting, University of Pavia

Blood samples were collected and cardiac magnetic resonance imaging was performed prior to doxorubicin initiation and at 6 and 24 months. Biomarker clusters did not mediate an effect of atorvastatin on LVEF (p>0.05) Atorvastatin demonstrated very modest effects on oxidative/nitrosative stress biomarkers in this low cardiovascular risk population. Our findings provide potential mechanistic insight into the lack of effect of atorvastatin on LVEF in the PREVENT trial.

Encouragingly, we find that the combination of cisplatin and fluvastatin can alleviate this problem. FP NPs can degrade mutant p53 (mutp53) and efficiently trigger endoplasmic reticulum stress (ERS). In this study, we show that FP NPs relieve the inhibition of cisplatin chemotherapy caused by mutp53, exhibiting highly effective tumor suppression and improving the poor NSCLC prognosis.

P2, N=150, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting | Initiation date: Jan 2024 --> Apr 2024

P2/3, N=100, Completed, Tanta University | Recruiting --> Completed

P4, N=30, Recruiting, Mario Pérez Sayáns

In the treatment of patients with CRS Type-2, medium dose (20mg/day) atorvastatin can have the same therapeutic effect as the high dose (40mg/day) treatment. Medium dose has a good protective effect on the heart and kidneys of the patients, and helps to reduce inflammatory reactions and improve heart and kidney function.

P1, N=63, Completed, Chong Kun Dang Pharmaceutical | Not yet recruiting --> Completed

P2, N=50, Recruiting, Tianjin Medical University General Hospital

In this study, we developed biodegradable zwitterionic polymer-cloaked atorvastatin (ATV)-loaded ferric metal-organic frameworks (Fe-MOFs) for cancer treatment...This synergistic effect ultimately contributed to a lethal accumulation of LPO, causing cancer cell death. The findings both in vitro and in vivo suggested that this ferroptosis-inducing nanoplatform exhibited enhanced anticancer efficacy and preferable biocompatibility, which could provide a feasible strategy for anticancer therapy.

P1, N=15, Recruiting, Children's Mercy Hospital Kansas City

P1, N=50, Active, not recruiting, Joaquina Baranda | Recruiting --> Active, not recruiting

In addition, it is actively influenced by common anti-breast cancer drugs like paclitaxel, simvastatin, and gefitinib. This review aims to systematically elucidate the role of FOXO3a in breast cancer. Additionally, it reviews the interaction of FOXO3a and its upstream and downstream signaling pathway-related molecules to uncover potential therapeutic drugs and related regulatory factors for breast cancer treatment by regulating FOXO3a.

Our data strongly supports the presence of synergy between MTF and SIM in OC cells. The combination's effect is associated with the dysregulation of genes in the key regulators AMPK and mTOR alongside other interconnected pathways.

P=N/A, N=8606, Not yet recruiting, Boryung Pharmaceutical Co., Ltd